NAMAPA
Latest Content
As more adalimumab biosimilars are poised to enter the market, manufacturers, payers, and patient advocates are preparing to navigate potentially turbulent waters.
Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.
Health care advocates provide a vital service for patients who are managing chronic conditions.
Advertisement
Advertisement
Trending on Drug Topics
1
Trump Signs Order Narrowing Childhood Vaccine Recommendations
2
The Effects of COVID-19 Influencing the Development of Vaccines
3
The FTC’s Targeting of Drug-Inflating PBM Practices
4
Experts Uncertain of GLP-1s’ Long-Term Clinical Benefits
5